急性髓系白血病FLT3抑制剂及耐药机制的研究进展
Research progress of FLT3 inhibitors and drug resistance mechanisms in acute myeloid leukemia
吴庭恺 1任崇崇 1张婉婉 1刘蓓2
作者信息
- 1. 兰州大学第一临床医学院,兰州 730000,甘肃
- 2. 兰州大学第一医院血液科,兰州 730000,甘肃
- 折叠
摘要
FMS样酪氨酸激酶3(FMS-like tyrosine ki-nase 3,FLT3)基因突变在急性髓系白血病(AML)中发生率最高,且与不良预后相关.针对FLT3突变已经开发了多种靶向抑制剂,且取得了较好的临床疗效.但随之出现的耐药为FLT3靶向治疗AML带来新的挑战.本文将对FLT3突变在AML中的病理和预后作用、目前常用FLT3抑制剂(Ⅰ型和Ⅱ型)的研究进展、F LT3抑制剂耐药的机制及如何克服作一综述.
Abstract
The FMS-like tyrosine kinase 3(FLT3)gene mutation is the most common genetic muta-tion in acute myeloid leukemia(AML)and is associ-ated with poor prognosis.Various targeted inhibi-tors have been developed for FLT3 mutations and have shown promising clinical efficacy.However,the emergence of resistance poses new challenges for targeted therapy in AML.This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML,the current research progress on commonly used FLT3 inhibitors(type Ⅰand type Ⅱ),the mechanisms of FLT3 inhibitor resis-tance,and strategies for overcoming resistance.
关键词
急性髓系白血病/FLT3抑制剂/耐药Key words
acute myeloid leukemia/FLT3 inhibi-tors/drug resistance引用本文复制引用
基金项目
甘肃省自然科学基金(18JR3RA356)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据